Keywords
Viabilidad celular
Líneas celulares tumorales
Homeopatía
Citotoxicidad
Prostatic Neoplasms
Cell Viability
Tumor Cell Lines
Homeopathy
Cytotoxicity
Abstract
Introducción: El cáncer de próstata es una de las principales causas de mortalidad por cáncer en hombres. Debido al interés creciente por terapias complementarias, el medicamento homeopático Vidatox® 30CH, elaborado a partir del veneno del escorpión Rhopalurus junceus, ha sido objeto de estudio por sus posibles efectos biológicos. Objetivo: Evaluar la viabilidad celular in vitro de líneas celulares humanas de cáncer de próstata expuestas a diferentes concentraciones de Vidatox® 30CH. Material y métodos: El presente estudio experimental fue realizado en las líneas celulares humanas LNCaP y PC-3, las cuales fueron expuestas a Vidatox® 30CH en concentraciones de 100%, 50%, 25%, 12.5% y 6.25%, además de un control (etanol 33%). La viabilidad celular se evaluó mediante los ensayos MTT y cristal violeta a las 24, 48 y 72 horas posteriores a la exposición. Los resultados se analizaron mediante ANOVA de una vía y prueba post hoc de Tukey. Resultados y Discusión: Las concentraciones de 100% y 50% mostraron una disminución de la viabilidad celular, particularmente en la línea PC-3. Las concentraciones de 12.5% y 6.25% presentaron porcentajes de viabilidad similares o incluso superiores al control. El análisis de varianza mostró diferencias significativas entre tratamientos (p = 0.01). La reducción de la viabilidad observada en células PC-3 a concentraciones elevadas coincide con reportes sobre efectos citotóxicos de compuestos derivados de venenos de escorpión; sin embargo, la ausencia de cambios relevantes en células LNCaP indica que este efecto no es uniforme entre las líneas celulares evaluadas. Conclusiones: Bajo las condiciones experimentales estudiadas, Vidatox® 30CH redujo la viabilidad celular de la línea PC-3 a concentraciones elevadas, mientras que en la línea LNCaP no produjo cambios relevantes. Estos hallazgos sugieren un posible efecto dependiente de la concentración y del tipo celular. Se requieren estudios adicionales para confirmar estos resultados y esclarecer los mecanismos biológicos involucrados.
Effects of Vidatox® 30CH on the in vitro viability of prostate cancer cell lines
Abstract
Introduction: Prostate cancer is one of the leading causes of cancer-related death in men. Due to the growing interest in complementary therapies, the homeopathic medicine Vidatox® 30CH, derived from the venom of the Rhopalurus junceus scorpion, has been studied for its potential biological effects. Objective: To evaluate the in vitro cell viability of human prostate cancer cell lines exposed to different concentrations of Vidatox® 30CH. Materials and methods: An experimental study was conducted using the human cell lines LNCaP and PC-3. The cells were exposed to Vidatox® 30CH at concentrations of 100%, 50%, 25%, 12.5%, and 6.25%, in addition to a control. Cell viability was assessed using the MTT and crystal violet assays at 24, 48, 26 Vol. 2026-2 / Revista Médica de la Universidad Veracruzana and 72 hours post-exposure. The results were analyzed using one-way ANOVA and Tukey’s post-hoc test. Results and Discussion: Concentrations of 100% and 50% showed a decrease in cell viability, particularly in the PC-3 cell line. Concentrations of 12.5% and 6.25% showed viability percentages similar to or higher than the control. Analysis of variance showed significant differences between treatments (p = 0.01). The reduction in viability observed in PC-3 cells at high concentrations is consistent with reports on the cytotoxic effects of compounds derived from scorpion venom; however, the absence of relevant changes in LNCaP cells indicates that this effect is not uniform among the cell lines evaluated. Conclusions: Under the experimental conditions studied, Vidatox® 30CH reduced cell viability in the PC-3 cell line at high concentrations, while in the LNCaP cell line it did not produce relevant changes. These findings suggest a possible concentration- and cell-type-dependent effect. Further studies are required to confirm these results and elucidate the biological mechanisms involved.
References
Akin, O., Woo, S., Oto, A., Allen, B. C., Avery, R., Barker, S. J., Gerena, M., Halpern, D. J., Gettle, L. M., Rosenthal, S. A., Taneja, S. S., Turkbey, B., Whitworth, P., & Nikolaidis, P. (2023). ACR Appropriateness Criteria® pretreatment detection, surveillance, and staging of prostate cancer: 2022 update. Journal of the American College of Radiology, 20(5), S187–S210. https://doi.org/10.1016/j.jacr.2023.02.010
Berenguer, C. V., Pereira, F., Câmara, J. S., & Pereira, J. A. M. (2023). Underlying features of prostate cancer—Statistics, risk factors, and emerging methods for its diagnosis. Current Oncology, 30(2), 2300–2321. https://doi.org/10.3390/curroncol30020178
Bergengren, O., Pekala, K. R., Matsoukas, K., Fainberg, J., Mungovan, S. F., Bratt, O., Bray, F., Brawley, O., Luckenbaugh, A. N., Mucci, L., cancer epidemiology and risk factors—A systematic review. European Urology, 84(2), 191–206. https://doi.org/10.1016/j.eururo.2023.04.021
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21834
Casamayor Laime, Z., Guevara García, M. M., & González Laime, S. (2020). Empleo del Vidatox® 30CH en el alivio del dolor y otros síntomas de enfermedades inflamatorias. Revista Cubana de Farmacia, 53(4). https://orcid.org/0000-0002-1684-1811
Castro Murillo, M., & González Betancur, J. (2016). OECD guideline for the testing of chemicals (Guideline 476). Organisation for Economic Co-operation and Development. http://www.oecd.org/termsandconditions/
Colella, F., Scillitani, G., & Pierri, C. L. (2021). Sweet as honey, bitter as bile: Mitochondriotoxic peptides and other therapeutic proteins isolated from animal tissues, for dealing with mitochondrial apoptosis. Toxicology, 447, 152612. https://doi.org/10.1016/j.tox.2020.152612
Crusca, E., Basso, L. G. M., Altei, W. F., & Marchetto, R. (2018). Biophysical characterization and antitumor activity of synthetic Pantinin peptides from scorpion venom. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1860(11), 2530–2540. https://doi.org/10.1016/j.bbamem.2018.08.012
Damadoğlu, E., Irmak, İ., & Kalyoncu, A. F. (2021). Cuban blue scorpion venom and lung carcinoma: Is it always true what does not kill me makes me stronger? Turkish Thoracic Journal, 22(3), 265–266. https://doi.org/10.5152/turkthoracj.2021.20202
Del Río Portilla, F., & Mayorga Flores, M. (2020, 19 de noviembre). En proceso de patente, veneno de alacrán que inhibe propagación de cáncer en piel, mama y próstata. Gaceta UNAM, 5156, 4–5. https://www.gaceta.unam.mx/wp-content/uploads/2020/11/201119.pdf
Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2024). Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. https://gco.iarc.who.int/
García-Gómez, B. I., Coronas, F. I. V., Restano-Cassulini, R., Rodríguez, R. R., & Possani, L. D. (2011). Biochemical and molecular characterization of the venom from the Cuban scorpion Rhopalurus junceus. Toxicon, 58(1), 18–27. https://doi.org/10.1016/j.toxicon.2011.04.011
Giovannini, C., Baglioni, M., Baron Toaldo, M., Cescon, M., Bolondi, L., & Gramantieri, L. (2017). Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Scientific Reports, 7(1), 44685. https://doi.org/10.1038/srep44685
LABIOFAM. (2024). Vidatox® 30 CH. https://www.vidatox.com.mx/
Michalski, J. M., Pisansky, T. M., Lawton, C. A., & Potters, L. (2021). Prostate cancer. En J. E. Tepper & L. L. Gunderson (Eds.), Gunderson & Tepper’s clinical radiation oncology (pp. 1054–1114). Elsevier. National Cancer Institute. (2023). Cancer stat facts: Prostate cancer. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/prost.html
National Institute for Health and Care Excellence. (2019). Prostate cancer: Diagnosis and management (NG131). https://www.nice.org.uk/guidance/ng131
Oczkowski, M., Dziendzikowska, K., Pasternak-Winiarska, A., Włodarek, D., & Gromadzka-Ostrowska, J. (2021). Dietary factors and prostate cancer development, progression, and reduction. Nutrients, 13(2), 496. https://doi.org/10.3390/nu13020496
Procuraduría Federal del Consumidor. (2019, 17 de junio). Cuida tu próstata y regálate vida. Gobierno de México. https://www.gob.mx/profeco/documentos/cuida-tu-prostata-y-regalate-vida
Satitmanwiwat, S., Changsangfa, C., Khanuengthong, A., Promthep, K., Roytrakul, S., Arpornsuwan, T., Saikhun, K., & Sritanaudomchai, H. (2016). The scorpion venom peptide BmKn2 induces apoptosis in cancerous but not in normal human oral cells. Biomedicine & Pharmacotherapy, 84, 1044–1050. https://doi.org/10.1016/j.biopha.2016.10.041
Srairi-Abid, N., Othman, H., Aissaoui, D., & BenAissa, R. (2019). Anti-tumoral effect of scorpion peptides: Emerging new cellular targets and signaling pathways. Cell Calcium, 80, 160–174. https://doi.org/10.1016/j.ceca.2019.05.003
Uzair, B., Bint-e-Irshad, S., Khan, B. A., Azad, B., Mahmood, T., Rehman, M. U., & Braga, V. A. (2018). Scorpion venom peptides as a potential source for human drug candidates. Protein & Peptide Letters, 25(7), 702–708. https://doi.org/10.2174/0929866525666180614114307
Wasim, S., Lee, S. Y., & Kim, J. (2022). Complexities of prostate cancer. International Journal of Molecular Sciences, 23(22), 14257. https://doi.org/10.3390/ijms232214257
Wei, J. T., Barocas, D. A., Carlsson, S. V., Coakley, F. V., Eggener, S. E., Etzioni, R., Fine, S. W., Han, M., Konety, B. R., Miner, M. M., Moses, K. A., Nissenberg, G., Pinto, P. A., Salami, S. S., Souter, L. H., Thompson, I. M., & Lin, D. W. (2023). Early detection of prostate cancer: AUA/SUO guideline (2023). The Journal of Urology, 210(1), 46–53. https://doi.org/10.1097/JU.0000000000003491
Yanes Chacón, A. N., Villalobos Campos, N. P., & Cubas González, S.A. (2023). Cáncer de próstata: Una perspectiva global. Revista Médica Sinergia, 8(12), e1124. https://doi.org/10.31434/rms.